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Background: Essential tremor (ET) patients regularly inquire about their prognosis. 
Therefore, physicians have cause to review available medical literature for meaningful 
answers. Longitudinal studies are ideally suited to provide a glimpse into the evolution 
of tremor. Despite its high prevalence, there are surprisingly few longitudinal clinical 
studies of ET. Furthermore, none of them provide data from the patients’ perspective. 
Understanding the patient vantage point is valuable as it is the starting point of person-
alized medicine. Given the progressive nature of ET, we hypothesized that many patients 
will experience an increase in symptom severity over time. However, due to a lack of clin-
ical data, the exact nature of this progression is unclear. For example, whether patients 
experience a worsening at each time interval is simply not known. In this longitudinal 
study, we assessed whether ET patients felt that their symptoms had worsened between 
each follow-up evaluation and try to identify specific clinical characteristics associated 
with this experience.
Methods: A cohort of 164 ET cases enrolled in a prospective, longitudinal research 
study. After a baseline in-person assessment, they received regular telephone evalua-
tions for up to 5.25 years, beginning in 2009. During each follow-up evaluation, cases 
answered the question, “has your ET worsened since our last call?”
results: Two-thirds [104 (63.4%)] of ET cases reported worsening at one-half or more of 
their follow-up evaluations. Furthermore, one in four cases [44 (26.8%)] reported wors-
ening at every follow-up evaluation. Self-reported worsening was not associated with 
any of the baseline clinical variables assessed, including age, gender, tremor duration, 
age at tremor onset, or total tremor score.
conclusion: Little has been written from the patients’ perspective on progression of 
ET. When followed longitudinally at regular intervals, a majority of ET cases we studied 
reported worsening one-half or more of the time; furthermore, one in four cases reported 
worsening at each and every assessment, indicating that they felt they were inexorably 
getting worse and worse with time. That there is so much self-reported worsening in 
ET argues against the notion that this is a static and benign condition. It suggests that 
patients experience it as a condition that worsens regularly and consistently.
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inTrODUcTiOn
Essential tremor (ET) is one of the most prevalent movement dis-
orders and is commonly encountered in clinical practice (1–3). As 
it is a chronic and progressive disorder, patients regularly inquire 
about their prognosis. Hence, physicians have cause to review 
available medical literature for meaningful answers. Longitudinal 
studies are ideally suited to provide a glimpse into the evolution 
of tremor in ET patients. Despite this, there are surprisingly few 
longitudinal clinical studies of ET. Indeed, there are five longi-
tudinal studies (4–8), although one was a retrospective review 
of clinical records (4). Four of these studies reported cohorts of 
modest size (<50 cases) (4–6, 8). One of these studies focused 
on baseline prognostic factors to predict arm tremor severity 
over time (4); another examined the change in tremor frequency 
using accelerometry and electromyography (5). Only one study 
evaluated the change in arm tremor severity using a standardized 
clinical rating scale (6). The two other studies did not provide any 
data on change in severity of arm tremor over time (7, 8). Most 
germane to the current analyses is that none provided data from 
the patients’ perspective.
In actuality, there is remarkably little written about either 
the experience of tremor or the experience of the evolution 
of tremor from the perspective of the ET patient. Although a 
patient-centered approach is less objective than the one provided 
by clinician-assigned ratings or tremor analysis, understanding 
the patient vantage point is valuable as it is a central ingredient as 
well as the starting point of personalized medicine (9).
Given the progressive nature of this disorder, we hypothesize 
that many patients will experience an increase in symptom severity 
over time. However, due to a lack of clinical data, the exact nature 
of this progression is not clear. Whether patients experience a 
worsening at each time interval is simply not known. As part of 
an ongoing clinical research study, we prospectively collected 
longitudinal data at regular intervals on self-reported symptom 
progression. At each interval, 164 cases were asked by telephone 
“has your ET worsened since our last call?” The goal of this report 
was to (1) assess whether ET patients feel their symptoms worsen 
at each interval and (2) identify the specific clinical characteristics 
that may be associated with the experience of worsening.
MaTerials anD MeThODs
case ascertainment
Essential tremor cases were recruited through the essential 
tremor centralized brain repository (ETCBR), which serves as a 
centralized repository for the prospective collection and study of 
brains of ET cases throughout the United States (10). ET cases 
were recruited as future brain donors through advertisements on 
patient advocacy group websites and the ETCBR website (www.
essentialtremor.us). Each recruited case underwent an in-person 
baseline evaluation. This was followed by regular follow-up 
telephone assessments, the purpose of which was to update clini-
cal information. Enrollment of the wave of cases reported here 
began in March of 2009 and ended in April of 2011. Follow-up 
has continued to present.
Baseline evaluation
Once enrolled, ET cases were visited in their homes by a trained 
research assistant, who performed a detailed baseline evalu-
ation. Each case signed an informed consent form approved 
by the Internal Review Board of Columbia University. The 
research assistant administered a series of semistructured 
clinical questionnaires eliciting demographic and medical 
information. Medical comorbidity was evaluated using the 
Cumulative Illness Rating Scale (CIRS, range 0–42) (11). 
To briefly assess cognition, the Folstein Mini-Mental State 
Examination (MMSE, range 0–30) was administered (12). 
Additionally, each case drew four standardized, hand-drawn 
Archimedes spirals (two right, two left), each on an 8.5″ × 11″ 
sheet of paper.
The research assistant obtained a standardized, videotaped 
neurological examination, including a detailed assessment of 
tremor (13). The videotaped examination included assessments 
of postural tremor (two positions), kinetic tremor (five activities 
with each arm), and intention tremor of the arms, as well as 
head tremor. Tremor was rated by a senior movement disorder 
neurologist (Elan D. Louis) using a reliable (14) and valid (15) 
clinical rating scale, which included ratings from 0 to 3 for each 
of 12 items. A total tremor score (range 0–36) (6), which is a 
measure of action tremor, was calculated based on these ratings. 
The videotaped examination also included the motor portion of 
the Unified Parkinson’s Disease Rating Scale (16).
eT Diagnoses
Essential tremor diagnoses were carefully assigned and 
then confirmed using the following methods. First, the vast 
majority of cases were diagnosed clinically with ET by their 
treating physician (either by their primary health physicians 
or neurologists); the remaining few were self-diagnosed cases 
and included individuals with a strong family history of ET. 
Second, as noted above, cases were asked to complete a series 
of semistructured clinical questionnaires (demographic data, 
general medical data including medications, and tremor-
specific data), which included data on age of onset and family 
history information. As noted above, Archimedes spirals were 
also drawn. These data were supplemented with additional 
clinical information (from clinical records, treating physicians, 
and family members). ET diagnoses were then confirmed by a 
senior neurologist specializing in movement disorders (Elan 
D. Louis) who used the following criteria: (1) moderate or 
greater amplitude arm tremor (rating ≥2) in at least one of the 
submitted Archimedes spirals; (2) no history of Parkinson’s 
disease or dystonia; and (3) no other etiology for tremor 
(e.g., medications, hyperthyroidism). Third, as noted above, 
ET cases underwent a standardized, videotaped neurological 
examination. Each videotape was reviewed (Elan D. Louis), and 
based on the questionnaire and videotape data, the diagnosis 
of ET was re-examined in each case using published diagnostic 
criteria (moderate or greater amplitude kinetic tremor (tremor 
rating ≥2) during three or more videotaped activities or a head 
tremor in the absence of Parkinson’s disease or other known 
causes) (14, 15, 17).
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Follow-up evaluations
Cases received regular follow-up evaluations by telephone. 
The protocol was approved by the Internal Review Boards of 
Columbia and Yale Universities. During the initial 3 years of the 
study, these evaluations were performed at 6-month intervals. 
After that point, the interval was lengthened to 9 months due to 
concerns about participant fatigue.
During each follow-up evaluation, the research assistant 
assessed progression of symptoms. Thus, cases answered the ques-
tion, “has your ET worsened since our last call?” If cases answered 
“Yes” to this question, the research assistant asked them, “how 
has your ET worsened?” Cases were also asked about changes in 
medications and ethanol consumption, and they submitted four 
new standardized Archimedes spirals (13). Finally, they were 
asked a series of screening questions for Parkinson’s disease and 
dystonia. If any screening question was positive for Parkinson’s 
disease or dystonia or if a spiral showed signs of micrographia, the 
research assistant revisited the case at home to obtain a follow-up 
videotaped neurological examination.
additional evaluations
Medications were recorded at baseline and each follow-up 
telephone interview. In order to consider the potential effects of 
medication changes on the reported change in tremor symptoms, 
a “medication change score” was created. The medication list of 
each case was reviewed to identify tremorogenic and tremor-
reducing medications. A medication was deemed tremorogenic 
based on previously published reviews (18) and included lithium, 
β-adrenergic agonists, thyroxine, and other agents. Similarly, a 
medication was labeled as tremor reducing based on published 
data (19). Each tremorogenic medication was assigned a value of 
1; also, each tremor-reducing medication, a value of −1. A base-
line score was calculated as the sum of all these values at baseline, 
and a follow-up score was calculated as the sum of all these values 
at the most recent follow-up evaluation. The final “medication 
change score” was calculated as the difference between the base-
line medication score and the most recent follow-up medication 
score; a negative value indicated greater use of tremor-reducing 
medication at follow-up.
Similarly, to consider potential effects of changes in daily etha-
nol intake on reported change in tremor symptoms, a “change in 
ethanol intake score” was created. This was based on the average 
number of drinks per week that each case reported consum-
ing at each evaluation. The change in ethanol intake score was 
calculated as the change in number of drinks per week reported 
between baseline and the most recent follow-up.
Finally, to obtain a more objective measure of change in 
tremor severity with time, two trained research assistants (Jesús 
Gutierrez and Jemin Park) rated all of the baseline and most 
recent follow-up spirals using the Bain and Findley 10-point scale 
(0 = no detectable tremor to 9 = severe tremor) (20). This rating 
scale has been validated in previous studies assessing tremor 
severity (21–23). The two research assistants were trained by 
independently rating 50 Archimedes spirals, and their agreement 
with those of the senior movement disorders neurologist was sub-
stantial (24) [weighted kappa (κ) = 0.63 and 0.64]. To assess the 
change of spiral ratings over time, a “change in total spiral score” 
was calculated. Each case submitted two right hand spirals and 
two left hand spirals. The 0–9 ratings of each spiral were averaged. 
The change in total spiral score was calculated as the difference 
between the baseline and the most recent follow-up scores.
Final case selection
Of the 177 cases who had a baseline evaluation, 13 (7.3%) were 
excluded due to lack of follow-up data (5 deaths, 1 moved 
outside of the United States, 4 withdrew due to loss of interest, 
1 co-diagnosed with dystonia, and 2 miscellaneous). The final 
sample for analysis (164 ET cases) was similar to the 13 excluded 
cases in terms of baseline total tremor score (23.8  ±  6.2 vs. 
22.6 ± 9.4, p = 0.56) and age at onset of tremor (42.6 ± −23.0 
vs. 38.4 ± 20.7 years, p = 0.60). They did not differ by education 
(15.0 ± 3.2 vs. 13.4 ± 3.7 years, p = 0.18) or gender [62 (37.8%) 
women vs. 7 (53.8%) women, p = 0.25]. The two groups differed 
by age (83.3 ± 5.6 vs. 88.7 ± 6.3 years, p < 0.01).
statistical analyses
Statistical analyses were performed using SPSS (version 21.0; 
Chicago, IL, USA). The main variable of interest, self-reported 
worsening was not normally distributed (Kolmogorov–Smirnov 
test = 0.13, p < 0.01). Therefore, to explore the demographic and 
clinical correlates of the cases’ self-reported worsening, we used 
Spearman’s correlation coefficients and the Mann–Whitney test. 
Subsequently, we distributed cases into quartiles based on the 
percentage of time that they reported worsening. We compared 
quartiles by demographic and clinical variables using chi-square 
tests and one-way analysis of variance (ANOVA) when variables 
were normally distributed. For measures that were not normally 
distributed, non-parametric approaches were used (e.g., Kruskal–
Wallis test). The Jonckheere–Terpstra test was used when we 
tested hypotheses that included a priori ordering.
When we explored the correlation between percentage of 
times cases reported worsening and change in total spiral scores, 
we also stratified our analysis by whether or not cases were taking 
tremor-reducing medications.
resUlTs
case characteristics
The mean baseline age of ET cases was 83.3 years, and the mean 
age at tremor onset was 42.6 years (Table 1). On average, ET cases 
completed 6.8 follow-up assessments (median = 7, range = 1–10) 
spanning an average time interval of 3.7  years (median =  4.3, 
range = 0.5–5.25 years).
self-reported Worsening
Of the 164 cases, 44 (26.8%) reported worsening of symptoms at 
every follow-up interval, 104 (63.4%) reported worsening during 
one-half or more of the follow-up intervals, and 145 (88.4%) 
reported worsening at one or more follow-up intervals. Only 19 
(11.6%) never reported worsening. Data are shown (Figure 1). 
We obtained similar results when we restricted our analysis to 
FigUre 1 | Percentage of times that cases reported worsening per follow-up interval.
TaBle 1 | Baseline demographic and clinical features of 164 eT cases.
Baseline age (years) 83.3 ± 5.6 [84]
Female gender 102 (62.2)
Education (years) 15.0 ± 3.2 [16]
Family history of ET 42 (25.6)
Tremor duration (years) 40.7 ± 22.5 [35.5]
Age at tremor onset (years) 42.6 ± 23.0 [45]
Total tremor score 23.8 ± 6.2 [23.5]
Data are mean ± SD [median] or number (percentage).
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32 cases who were never on any medications for the treatment 
of tremor.
When cases reported worsening of symptoms, they were asked 
“how has your ET worsened?” Their open-ended responses were 
collapsed into the following basic categories (Table  2): I am 
shaking more (34.0%), certain activities are harder to accomplish 
(33.1%), my medicine is not working as well (6.0%), balance 
issues (5.9%), my tremor is harder to control (3.3%), and other/
miscellaneous (17.7%).
clinical correlates of self-reported 
Worsening
To assess the clinical correlates of self-reported worsening, we 
performed several analyses. First, we assessed the correlation 
between percentage of times that each case reported worsening 
and a range of demographic and clinical variables (Table 3). There 
was no association between worsening of symptoms and baseline 
age or gender (Table 3). There was a marginally significant nega-
tive correlation between years of education and reported worsen-
ing (Spearman’s rho = −0.14, p =  0.08). Similarly, medication 
change score and reported worsening were marginally correlated 
(Spearman’s rho = −0.12, p = 0.12). There was also a marginally 
significant positive correlation between CIRS scores and reported 
worsening (Spearman’s rho = 0.12, p = 0.12) and MMSE scores 
and reported worsening (Spearman’s rho = 0.13, p = 0.10). There 
was no correlation between reported worsening and any of the 
other clinical features (e.g., tremor duration, age at tremor onset, 
and total tremor score, Table  3). Finally, we divided our cases 
into two groups: early tremor onset (defined by tremor onset at 
the age of ≤40 years) and late tremor onset (tremor onset at the 
age of >40 years) (25). There were no differences between these 
two groups when we compared the percentage of times that each 
case reported worsening (64.3 ± 31.4 vs. 60.5 ± 36.3, p = 0.67).
Second, ET cases were divided into quartiles based on the per-
centage of times they had indicated worsening of symptoms dur-
ing follow-ups (Table 4). The analysis showed that the quartiles 
were similar in terms of basic demographic variables (baseline 
age, gender, education, family history, Table 4). There were no 
significant differences amongst the quartiles when we compared 
them by tremor duration, age at tremor onset, and total tremor 
score (Table 4). The quartiles did not differ by CIRS scores. The 
change in ethanol intake score differed marginally across quartiles 
but not in an ordinal manner. There was a marginally significant 
decrease in medication change score with increasing quartile; 
in other words, greater self-reported worsening was associated 
with greater use of tremor-reducing medication from baseline to 
follow-up. There was no progression of MMSE scores by quartile 
(Table 4).
correlate of self-reported Worsening  
and change in spiral scores
We also assessed the correlation between subjective worsening 
and an objective measure of worsening (i.e., change in spiral 
scores). As described above, two of the authors rated all of the 
spirals obtained at baseline and at the most recent follow-up 
evaluations using the Bain and Findley 10-point scale (20) and 
TaBle 2 | responses to follow-up question, “how has your essential tremor worsened?”.
response category sample quote from cases number (%) of responses in 
each category (data summed 
from all follow-up intervals)
I am shaking more “I am shaking more in every way” 261 (34.0)
“Shaking more in hands and legs”
“Voice is more tremulous, as are hands”
Certain activities are harder to accomplish “Writing is impossible; eating is a real problem” 254 (33.1)
“Hard to write with one hand; no sense of taste”
My medicine is not working as well “Propranolol doesn’t help as much as it used to” 46 (6.0)
“Nadolol is no longer effective”
Balance issues “Balance is shot; walking is difficult” 45 (5.9)
“Badly affected balance; walking unsteady”
My tremor is harder to control “Shaking is harder to control” 25 (3.3)
“Used to be controlled better than it is now”
Other/miscellaneous “No way of answering: I’ve changed meds so much I can’t tell which is which” 136 (17.7)
“Only when agitated”
“Can’t judge”
“Some days worse than others”
TaBle 3 | clinical correlates of self-reported worsening.
correlation with percentage 
of times that cases reported 
worsening or mean ± sD 
[median] of percentage of times 
that cases reported worsening
p-Value
Demographic variables
Age (years) r = −0.01 0.90a
Gender
Male 59.3 ± 35.2 [66.7] 0.40b
Female 63.8 ± 33.7 [71.4]
Education (years) r = −0.14 0.08a
Family history of ET
Yes 67.1 ± 35.7 [75.0] 0.19b
No 60.4 ± 33.7 [66.7]
Tremor duration and severity
Tremor duration (years) r = 0.003 0.97a
Age at tremor onset (years) r = 0.003 0.97a
Total tremor score r = 0.04 0.60a
Change in total spiral score r = 0.08 0.35a
Overall health and medications
CIRS score r = 0.12 0.12a
Change in ethanol intake score r = 0.03 0.69a
Medication change score r = −0.12 0.12a
cognitive screen
MMSE score r = 0.13 0.10a
Unless indicated otherwise, all values are baseline values.
Data are mean ± SD [median] or Spearman’s rho.
CIRS, Cumulative Illness Rating Scale (range 0–42); MMSE, Folstein Mini Mental State 
Examination (range 0–30).
aSpearman’s rho (r).
bMann–Whitney test.
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calculated a change in total spiral score for each case. We then 
explored the correlation between the change in total spiral score 
and the percentage of times our cases reported worsening. There 
was no correlation (Spearman’s r = 0.08, p = 0.35).
In order to consider the potential impact of ET treatments 
on these analyses, we performed sensitivity analyses. First, we 
restricted the analysis to those cases (N =  32) who had never 
taken tremor-reducing medications, and this produced similar 
results (Spearman’s r = 0.19, p = 0.37, i.e., no correlation between 
percentage of times our cases reported worsening and change in 
total spiral score). We repeated this analysis with cases (N = 116) 
who were always on at least one tremor-reducing medication. 
Again, there was no correlation between self-reported worsening 
and change in total spiral score (Spearman’s r = 0.07, p = 0.48).
DiscUssiOn
To our knowledge, this is the first prospective longitudinal study 
to examine the progression of symptoms from the perspective 
of the ET patient. On average, these ET cases were followed for 
4 years, and each case completed an average of seven follow-up 
assessments. During this time, most cases [145 (88.4%)] reported 
a worsening of their symptoms at least once. A majority [104 
cases (63.4%)] reported worsening during at least 50% of the 
follow-ups. Only a very small group [19 (11.6%)] did not report 
any worsening. A significant minority of cases [44 (26.8%)] 
reported worsening at every single follow-up, indicating that 
they felt they were inexorably getting worse and worse and worse 
with time.
That there is so much self-reported worsening in ET argues 
against the notion that this is a static and benign condition. It 
suggests that patients experience it as a condition that worsens 
consistently and regularly.
Two of the authors rated the spirals obtained at baseline and at 
the most recent follow-up evaluation using the Bain and Findley 
10-point scale (20) and calculated a change in total spiral score for 
each case. We did not find a correlation between the percentage 
of times our cases reported worsening and the change in total 
spiral score. This suggests that there is a subjective component to 
self-reported worsening that may not be borne out by independ-
ent objective evaluations. Another possibility is that the change 
noticed by the patients may be objectively small. A previous study 
6Gutierrez et al. Self-Reported Worsening Condition in ET
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that examined the change in spiral scores in ET patients using this 
same scale over time determined that scores increased at an aver-
age rate of 0.12 ± 0.23 points per year. The rate of increase was so 
small that the change in scores was apparent to a blinded neurolo-
gist only in cases that had been followed for at least 5 years (26). 
Given that the mean length of follow-up in our study was a little 
less than 4 years, a longer time span or a more precise rating scale 
might be needed to better assess this association. Additionally, 
since tremor in ET is known to vary from moment to moment 
(27), a different tool that provides continuous monitoring (vs. the 
snapshot in time that spiral drawing offers) may be required to 
overcome this intra-subject variability. Automated measures of 
tremor, such as wearable equipment, may be suited to capture the 
objective worsening of symptoms.
We looked at the association of self-reported worsening of 
symptoms and changes in ethanol consumption. In the past, the 
idea that ET patients self-medicate with ethanol leading to a higher 
consumption amongst patients with more severe symptoms had 
gained some traction. Although a marginal difference in change 
in ethanol consumption was apparent when cases were divided 
into quartiles based on the percentage of times they reported 
worsening, the mean scores in each quartile did not differ in 
an ordinal manner. Furthermore, we did not find a correlation 
between change in ethanol consumption and self-reported wors-
ening in our cohort. The absence of a correlation argues against 
the idea that ET patients are using ethanol to self-medicate and 
supports recently published data on this subject (28).
The results from this study can provide clinicians with use-
ful information to address their patients’ inquiries about the 
prognosis of their disease. As mentioned above, it appears that a 
significant portion of ET patients will experience what they feel 
as a progressive worsening of symptoms despite their physicians’ 
best efforts. Given this information, clinicians could benefit from 
setting appropriate expectations of treatment effects.
This study should be considered in the context of certain 
limitations. First, these cases were highly selected because many 
of them were ascertained through a disease-specific organiza-
tion and because they self-referred to the ETCBR as future brain 
donors. These cases may not be representative of the general ET 
patient population as they may suffer from more severe disease. 
Therefore, a community-based study would better estimate the 
progression of symptoms in the community. Second, although 
we tried to assess the impact of changes of individual medica-
tions throughout follow-up, we did not have access to infor-
mation on changes of dosages. To explore the possibility that 
changes of dosages may have affected our results, we repeated 
our analyses restricting the cases to those who were never on any 
medications. Self-reported worsening was similar to that which 
we reported in our main analysis. Finally, future longitudinal 
studies exploring self-reported progression of symptoms could 
benefit from the inclusion of additional health-related quality of 
life instruments, such as the Quality of Life in Essential Tremor 
(QUEST) questionnaire (29) or the EuroQol 5-Dimension 
questionnaire (30).
In summary, when followed longitudinally at regular intervals, 
most ET cases (88.4%) reported a worsening of their symptoms 
at least once, 63.4% reported worsening during at least 50% of 
the follow-ups and one in four cases reported worsening at every 
TaBle 4 | clinical correlates of reported worsening: quartile of worsening by demographic and clinical features.
Quartile First second Third Fourth p-Value
N 41 (25.0) 42 (25.6) 37 (22.6) 44 (26.8)
Percentage of time that cases reported worsening 12.0 ± 12.4 [11.1] 55.7 ± 10.1 [56.3] 79.9 ± 6.0 [80] 100 ± 0.0 [100]
Demographic variables
Age (years) 83.6 ± 6.5 [84.0] 83.4 ± 4.8 [84.0] 82.6 ± 5.4 [83.0] 83.7 ± 5.8 [83.5] 0.85a
Male gender 16 (39.0) 19 (45.2) 12 (32.4) 15 (34.1) 0.63b
Education (years) 15.5 ± 4.1 [16.0] 16.0 ± 3.6 [16.0] 14.4 ± 3.7 [14.0] 14.1 ± 4.7 [16.0] 0.30c
Family history of ET 10 (24.3) 8 (19.0) 9 (24.3) 15 (34.1) 0.45b
Tremor duration and severity
Tremor duration (years) 36.7 ± 23.6 [35.0] 45.9 ± 23.7 [40.0] 41.2 ± 18.8 [35.0] 39.1 ± 23.0 [32.5] 0.21c
Age at tremor onset (years) 46.9 ± 22.0 [48.0] 37.5 ± 24.3 [42.5] 41.5 ± 21.1 [45.0] 44.5 ± 24.2 [52.5] 0.21c
Total tremor score 22.5 ± 7.0 [23.3] 25.0 ± 5.3 [26.3] 24.6 ± 6.6 [24.3] 23.3 ± 5.8 [23.5] 0.27a
Change in total spiral score 0.17 ± 2.8 [0.13] −0.07 ± 2.7 [0.25] 0.13 ± 2.9 [0.75] 0.67 ± 2.4 [0.50] 0.80c
Overall health and medications
CIRS score 9.63 ± 5.4 [9.0] 10.7 ± 5.5 [11.0] 9.76 ± 4.9 [10.0] 11.6 ± 5.3 [12.0] 0.26c
Change in ethanol intake score −2.02 ± 4.9 [0.0] −5.9 ± 19.7 [−1.0] −1.64 ± 5.9 [0.0] −3.3 ± 13.5 [0.0] 0.06c
Medication change score 0.37 ± 0.9 [0.0] 0.21 ± 1.0 [0.0] 0.11 ± 0.8 [0.0] −0.07 ± 1.3 [0.0] 0.27c
0.05d
cognitive screen
MMSE score 26.4 ± 2.7 [27.0] 27.6 ± 1.9 [28.0] 27.1 ± 2.3 [27.0] 27.2 ± 4.4 [28.0] 0.12c
Unless indicated otherwise, all values are baseline values.
Data are mean ± SD [median] or number (percentage).
CIRS, Cumulative Illness Rating Scale (range 0–42); MMSE, Folstein Mini Mental State Examination (range 0–30).
aANOVA.
bChi-square test.
cKruskal–Wallis test.
dJonckheere–Terpstra test.
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single follow-up assessment, indicating that they felt they were 
inexorably getting worse and worse and worse with time.
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